CRISPR knockout studies further demonstrate that GCLC is essential for the survival of acute myeloid leukemia (AML) cells but less critical for normal hematopoietic cells, highlighting its selective therapeutic potential (43, 44). This evidence concerns the gene GCLC and acute myeloid leukemia.